Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 in advanced solid tumors
NCT04825392Phase 1Unknown
- Sponsor
- Taizhou Hanzhong Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pucotenlimab in solid tumor, sponsored by Taizhou Hanzhong Pharmaceuticals. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 at 24 months. Status: unknown.
02
Drugs
pucotenlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04825392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825392.